Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push

Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push Written by MarketBeat September 20, 2026 Add As Preferred Source Share Share Share This Article Link copied to clipboard. Close Image from MarketBeat Media, LLC. Key Points Pacific Biosciences expects approximately $40 million in savings next year from headcount reductions and lower non-recurring expenses, while maintaining its focus on clinical genomics, particularly carrier, newborn and rare-disease screening. The SPRQ-Nx reagent rollout lowers list prices by 30% and allows sequencing chips to be reused up to three times, but has temporarily reduced consumable revenue per instrument; PacBio expects pull-through and margins to recover by year-end as adoption improves. PacBio is prioritizing a high-throughput platform planned for launch later next year, viewing it as central to future revenue and margin growth, while shifting toward clinical, biopharma and other customers amid uncertain academic and government funding. Five stocks we like better than Pacific Biosciences of California . Deciphering Disruption: Inside Cathie Wood's Latest Plays Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion. Van Oene, who recently took the CEO role after more than five years at the company, said the company’s principal strategic opportunity is expanding in differentiated clinical applications, particularly germline genomics. He identified carrier screening, newborn screening and rare-disease testing as priority areas. Get PACB alerts: Sign Up Strategic Buy Lights Up This Biotech Stock: Time to Invest? “This is not me making a wholesale change on the strategy,” Van Oene said. “It really is … the execution.” Restructuring Savings and Product Priorities The company recently completed a restructuring intended to reduce cash burn. Van Oene said investors should expect Pacific Biosciences to deliver approximately $40 million in savings next year through headcount reductions and lower non-recurring expenses. He also said a near-term priority is stabilizing commercial and research-and-development teams affected by the restructuring. Product execution will center on the company’s SPRQ-Nx reagents, which began shipping at the end of May. The reagents enable customers to reuse a sequencing chip up to three times, a capability Van Oene described as significant for both customer pricing and the company’s gross margins. Pacific Biosciences lowered its list price by 30% with the rollout, according to Van Oene. He said early customer feedback has been encouraging, with strong results on first and second sequencing runs, though yields have been somewhat lower on third runs. The company is working with customers on workflow and timing considerations. Van Oene said the lower pricing is generating new projects, larger-scale discussions and, in some cases, expansions of customers’ Revio instrument fleets. However, he said the transition has reduced consumable pull-through per instrument to closer to $200,000 during the second quarter and expects that pressure to continue through the current quarter. He characterized the rollout as a two-quarter transition and said the company expects consumable revenue and annual pull-through to begin recovering by year-end. Successful adoption could also support gross-margin improvement, with Van Oene citing SPRQ-Nx as the company’s first product intended to more meaningfully increase margins. Clinical Growth and High-Throughput Development Van Oene said European hospitals and academic medical centers are already using whole-genome sequencing for rare disease at volumes reaching thousands of samples. In Europe, he sees a growing transition toward using HiFi sequencing as a frontline test rather than as...